/
CMMB
$1.62+$0.03 (+1.89%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$11.4M
7M shares
52-week range
$1.35 – $4.92
8% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Borrow rate
22.83%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-74.46
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $66.0K | $281.9K | $80.0K | $34.0K | $57.8K | $66.8K | $53.3K | $0 |
| Gross profit | −$65.8K | −$282.0K | −$80.0K | −$34.0K | −$57.8K | −$66.8K | −$53.3K | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $7.5M | $13.3M | $4.7M | $6.3M | $17.0M | $18.4M | $11.3K | $5.8M |
| Operating income | −$13.0M | −$19.6M | −$6.0M | −$12.4M | −$28.5M | −$25.5M | −$14.7M | −$9.6M |
| EBITDA | −$13.4M | −$26.9M | −$5.9M | −$12.3M | −$28.5M | −$25.4M | −$14.0M | −$9.5M |
| Net income | −$13.8M | −$27.2M | −$6.0M | −$12.5M | −$27.6M | −$24.2M | −$13.9M | −$9.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -87.09 | -63.20 | -25.21 | -4.80 | -9.68 | -8.22 | -3.12 | -1.42 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $24M | $-0.02 | $-0.02–$-0.02 | 1 |
| 2027 | $36M | $-0.03 | $-0.03–$-0.03 | 1 |
| 2028 | $0 | $-0.04 | $-0.04–$-0.04 | 1 |
| 2029 | $35M | $-0.04 | $-0.04–$-0.04 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.56
Price
$1.62
Implied downside
-4%
Peer comparison
Chemomab Therapeutics Ltd. American Depositary Share
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
www.chemomab.com- Employees
- 12
- IPO / List date
- Mar 17, 2021
- HQ
- TEL AVIV, L3
Held by traders on TradeandTell
No one on the platform currently holds CMMB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CMMB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-08-26 | 1-for-4reverse |
Recent trades on TradeandTell
No one on the platform has traded CMMB yet.
